These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 31710734)

  • 1. First-trimester screening for trisomies in pregnancies with vanishing twin.
    Chaveeva P; Wright A; Syngelaki A; Konstantinidou L; Wright D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2020 Mar; 55(3):326-331. PubMed ID: 31710734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for trisomy at 11-13 weeks' gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both.
    Mazer Zumaeta A; Wright A; Syngelaki A; Maritsa VA; Bardani E; Nicolaides KH
    Ultrasound Obstet Gynecol; 2020 Sep; 56(3):408-415. PubMed ID: 32621353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
    Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
    Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH
    Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
    Cicero S; Spencer K; Avgidou K; Faiola S; Nicolaides KH
    Prenat Diagn; 2005 Nov; 25(11):977-83. PubMed ID: 16245371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-trimester combined screening for trisomy 21 at 7-14 weeks' gestation.
    Wright D; Spencer K; Kagan K K; Tørring N; Petersen OB; Christou A; Kallikas J; Nicolaides KH
    Ultrasound Obstet Gynecol; 2010 Oct; 36(4):404-11. PubMed ID: 20658511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First trimester aneuploidy screening in the presence of a vanishing twin: implications for maternal serum markers.
    Spencer K; Staboulidou I; Nicolaides KH
    Prenat Diagn; 2010 Mar; 30(3):235-40. PubMed ID: 20066674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maternal serum free-beta-chorionic gonadotrophin, pregnancy-associated plasma protein-A and fetal nuchal translucency thickness at 10-13(+6) weeks in relation to co-variables in pregnant Saudi women.
    Ardawi MS; Nasrat HA; Rouzi AA; Qari MH; Al-Qahtani MH; Abuzenadah AM
    Prenat Diagn; 2007 Apr; 27(4):303-11. PubMed ID: 17269128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO; Wright D; Baker A; Sahota D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Jun; 31(6):618-24. PubMed ID: 18461550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-trimester combined screening for trisomy 21 with different combinations of placental growth factor, free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO; Hoopmann M; Abele H; Alkier R; Lüthgens K
    Ultrasound Obstet Gynecol; 2012 Nov; 40(5):530-5. PubMed ID: 22611005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of a 'vanishing twin' on biochemical and ultrasound first trimester screening markers for Down's syndrome in pregnancies conceived by assisted reproductive technology.
    Gjerris AC; Loft A; Pinborg A; Christiansen M; Tabor A
    Hum Reprod; 2009 Jan; 24(1):55-62. PubMed ID: 18835870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-trimester screening for trisomies by cfDNA testing of maternal blood in singleton and twin pregnancies: factors affecting test failure.
    Galeva S; Gil MM; Konstantinidou L; Akolekar R; Nicolaides KH
    Ultrasound Obstet Gynecol; 2019 Jun; 53(6):804-809. PubMed ID: 30977206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First trimester risk assessment for trisomy 21 in twin pregnancies combining nuchal translucency and first trimester biochemical markers.
    Prats P; Rodríguez I; Comas C; Puerto B
    Prenat Diagn; 2012 Oct; 32(10):927-32. PubMed ID: 22752980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The significance of maternal blood pregnancy-associated plasma protein A (PAPP-A) and free beta-subunit of human chorionic gonadotropin (β-hCG) levels for the risk assessment of fetal trisomy 18 during the first prenatal testing between 11 and 13+6 weeks of pregnancy.
    Ziolkowska K; Tobola-Wrobel K; Dydowicz P; Zurawski S; Pietryga M; Wysocka E
    Ginekol Pol; 2020; 91(12):748-754. PubMed ID: 33447994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medians and correction factors for biochemical and ultrasound markers in Chinese women undergoing first-trimester screening for trisomy 21.
    Sahota DS; Leung TY; Fung TY; Chan LW; Law LW; Lau TK
    Ultrasound Obstet Gynecol; 2009 Apr; 33(4):387-93. PubMed ID: 19306471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for aneuploidies by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-13+6 gestational weeks.
    Karadzov-Orlić N; Egić A; Filimonović D; Marinković M; Damnjanović-Pazin B; Milovanović Z; Joksić I; Branković S; Lukić R; Mandić V; Cerović N; Mojović D; Plamenac S; Stanković M; Maglić D; Mikovć Z
    Srp Arh Celok Lek; 2012; 140(9-10):606-11. PubMed ID: 23289277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prenatal screening for and diagnosis of aneuploidy in twin pregnancies.
    Audibert F; Gagnon A; ;
    J Obstet Gynaecol Can; 2011 Jul; 33(7):754-67. PubMed ID: 21749753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First- and second-trimester maternal serum markers of pre-eclampsia in twin pregnancy.
    Svirsky R; Levinsohn-Tavor O; Feldman N; Klog E; Cuckle H; Maymon R
    Ultrasound Obstet Gynecol; 2016 May; 47(5):560-4. PubMed ID: 25865365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Routine first-trimester combined screening for pre-eclampsia: pregnancy-associated plasma protein-A or placental growth factor?
    Noël L; Guy GP; Jones S; Forenc K; Buck E; Papageorghiou AT; Thilaganathan B
    Ultrasound Obstet Gynecol; 2021 Oct; 58(4):540-545. PubMed ID: 33998078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fetal loss after chorionic villus sampling in twin pregnancy.
    Elger T; Akolekar R; Syngelaki A; De Paco Matallana C; Molina FS; Gallardo Arozena M; Chaveeva P; Persico N; Accurti V; Kagan KO; Prodan N; Cruz J; Nicolaides KH
    Ultrasound Obstet Gynecol; 2021 Jul; 58(1):48-55. PubMed ID: 34038977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.